September 12th 2025
Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.
September 11th 2025
September 9th 2025
September 8th 2025
Overview of FLAURA and MARIPOSA-2 Clinical Trials
Dr. Kim reviews key clinical evidence from the FLAURA trial for osimertinib as a first-line therapy in EGFR+ metastatic NSCLC and discusses the MARIPOSA 2 trial supporting amivantamab with chemotherapy as the preferred second-line option.
The Impact of Molecular Testing on Treatment Choices for NSCLC
A discussion with Dr. Garon highlights patient selection for EGFR inhibitor therapy in EGFR+ NSCLC, emphasizing the critical role of biomarker testing, testing approaches, and overcoming barriers in community settings.
Robert’s Journey With EGFR+ Metastatic NSCLC
The video segment profiles a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope throughout his treatment journey.
The Role of Molecular Testing in Treatment Decisions for NSCLC
This video segment explores the critical role of biomarker testing in identifying patients with ALK-positive NSCLC, discussing the clinical characteristics that guide the use of ALK inhibitors and addressing challenges in implementing comprehensive molecular testing in community settings.
Sarah’s Journey With ALK+ Metastatic NSCLC
A panel of experts review a case of a 55-year-old mom and high school teacher who received lorlatinib for ALK+ NSCLC with brain metastases.